BEST OF PRECISION ONCOLOGY 2022 HYBRID CONFERENCE
This international flagship event will profile key foundational topics as well as emerging strategies associated with precision oncology. Attendees will be able to optimize diagnosis, treatment selection, and evidence-based management of patients with cancer using emerging diagnostic technologies to personalize and tailor therapies.
- State of the art tools for early detection of disease & monitoring molecularly target therapies
- Precision oncology biomarkers to guide therapeutic decision making
- Precision therapies and understanding the pathways to guide new therapies
Friday, October 28, 2022
- Timezone: America/Denver
- Date: Friday, October 28, 2022
- Time: 6:00 am - 2:00 pm
Join Us Live In Person
BMO Institute for Learning, Toronto
Registration for Healthcare professionals can be completed below. Industry representatives (both sponsor and non-sponsor) must contact Kelly Allan at email@example.com for registration and sponsorship opportunities.
In Person & Virtual Options Below:
About the Faculty
Dr. Daniel Renouf
Dr. Daniel Renouf is a medical oncologist and the Executive Medical Director at BC Cancer, Vancouver Centre. He is an Associate Professor at the University of British Columbia, Department of Medicine. He received his Doctor of Medicine from the University of Alberta and completed his internal medicine and medical oncology training at the University of British Columbia and BC Cancer. He undertook further training in early drug development and gastrointestinal oncology at Princess Margaret Hospital and the University of Toronto, and obtained a Masters of Public Health from Harvard University. Daniel’s research interests include developmental therapeutics, genomics, and biomarker development within gastrointestinal cancers, with a focus on pancreatic cancer. He is the leader of the BC Cancer Phase I program, the BC Cancer GI Tumour Group chair, the Co-Director of Pancreas Centre BC and is the Co-chair of the Canadian Cancer Trials Group Pancreatic Cancer disease group.
Dr. Michael Ong
Dr. Michael Ong is a clinician investigator and staff medical oncologist at The Ottawa Hospital Cancer Centre. His research focus includes targeted and immunotherapeutic drug development for prostate, melanoma, and bladder cancers, and he trained in drug development at The Royal Marsden Hospital and Institute of Cancer Research in the London England. He is an investigator on numerous international phase I and II trials and registry studies, research co-chair for the residency training program, and research ethics board member. Dr. Ong serves on the CCTG as a member of the GU trial development group, NCI prostate cancer task force, and IND liaison for melanoma, and is the 2021 recipient of the CCTG Elizabeth Eisenhauer Early Drug Development Young Investigator Award.